Compugen (CGEN) Cash & Equivalents (2009 - 2026)

Compugen has disclosed Cash & Equivalents across 18 years of filings, most recently posting $12.4 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $12.4 million, down 14.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.4 million (down 14.68% YoY), and the FY2025 annual result was $90.6 million, up 396.99% from the prior year.
• Cash & Equivalents came in at $12.4 million for Q1 2026 at Compugen, down from $90.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $90.6 million in Q4 2025 to a low of $6.5 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $12.2 million (2024), against an average of $18.2 million.
• Peak annual rise in Cash & Equivalents reached 396.99% in 2025, while the deepest fall reached 45.55% in 2025.
• Compugen's Cash & Equivalents stood at $11.1 million in 2022, then advanced by 25.6% to $13.9 million in 2023, then jumped by 31.24% to $18.2 million in 2024, then jumped by 396.99% to $90.6 million in 2025, then slumped by 86.27% to $12.4 million in 2026.
• The last three Cash & Equivalents figures came in at $12.4 million (Q1 2026), $90.6 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.